Randomized clinical trial: the effects of pregabalin for centrally mediated abdominal pain syndrome.

ABSTRACT:

Background

Pregabalin is worldwidely licensed for the treatment of a variety of pain syndromes and supposed to be a potential candidate for the centrally mediated abdominal pain syndrome (CAPS).

Objectives

To investigate the efficacy of pregabalin on nociceptive and emotional symptoms in CAPS patients.

Design

This is an open-label randomized controlled trial.

Methods

CAPS patients were randomized to receive pregabalin 75 mg (P group), pinaverium bromide 50 mg (PB group), or pregabalin combined pinaverium bromide regimen (P + PB group) three times daily for 4 weeks. Questionnaires were completed biweekly. The primary outcomes were defined as the average abdominal pain scores of severity and frequency at weeks 2 and 4. Secondary outcomes included the reduction in

SUBMITTER: Xu R 

PROVIDER: S-EPMC9989377 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature